MS Speaks

A blog from MedPage Today, January 29, 2014, includes a story indicating that a HIV drug, maraviroc (Selzentry), may be effective in treating PML in MS patients.

Amit Bar-Or, MD, of McGill University in Montreal, and colleagues reported in the New England Journal of Medicine this week that oral maraviroc (Selzentry), a CCR5 chemokine receptor antagonist for treating certain forms of HIV infection, helped a 49-year-old woman with MS avoid IRIS following plasmapheresis. The woman had undergone plasmapheresis because she had developed PML while taking natalizumab.

The entire article can be seen here.